{
    "clinical_study": {
        "@rank": "28283", 
        "arm_group": [
            {
                "arm_group_label": "Zoledronic acid plus First-line chemotherapy", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "First-line chemotherapy", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Pilot study of Zoledronic acid in combination with first-line chemotherapy in aged patients\n      with lung cancer. The purpose is to assess the effects of Zoledronic acid in combination\n      with first-line chemotherapy in aged patients with lung cancer on bone mineral density gain\n      in the lumbar spine and total hip."
        }, 
        "brief_title": "Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": "Lung Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent form\n\n          -  Age \u226570 years\n\n          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1\n\n          -  Histologically or cytologically confirmed lung cancer\n\n          -  Did not receive bisphosphonate treatment\n\n        Exclusion Criteria:\n\n          -  Appear relapse and metastasis\n\n          -  receive other bisphosphonate treatment\n\n          -  Active or uncontrolled infection\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737216", 
            "org_study_id": "HBTH201", 
            "secondary_id": "Hebei Tumor Hospital"
        }, 
        "intervention": [
            {
                "arm_group_label": "Zoledronic acid plus First-line chemotherapy", 
                "description": "Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression", 
                "intervention_name": "Zoledronic acid plus EP/TP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "First-line chemotherapy", 
                "description": "Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles", 
                "intervention_name": "EP/TP", 
                "intervention_type": "Drug", 
                "other_name": "First-line chemotherapy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zoledronic acid", 
                "Diphosphonates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Aged", 
            "patients"
        ], 
        "lastchanged_date": "December 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050011"
                }, 
                "name": "Hebei Tumor Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Hebei Tumor Hospital", 
            "last_name": "Wei Liu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival(PFS)", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737216"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival(OS)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Bone mineral density(BMD)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Quality of life(QOL)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Hebei Tumor Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Tumor Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}